Daily Alpha · Reddit
· Premarket Alpha · by Buzzberg Research
Reddit split between Nvidia dip buyers and put buyers, while separate posts covered Cisco's neocloud-free AI guide and hyperscaler capex outrunning revenue.
Themes on this desk
Nvidia dip vs puts
One r/wallstreetbets author bought 200 NVDA shares and 3 calls and another r/stocks author made a first-time NVDA purchase, while a r/smallstreetbets author bought puts citing Huang's departure, a DOJ probe and Asia data-center revenue risk
Highest engagement
by score · day changeCisco raised its hyperscaler-only AI revenue guide to $9 billion, keeping neoclouds out on purpose
The author summarizes Cisco's Q1 FY27 results, including the raised $9B hyperscaler-only AI revenue guide and the deliberate exclusion of neoclouds.
Cisco (CSCO) Q1 FY27: AI revenue guide raised to $9B, and neoclouds are kept out of it on purpose Cisco
The guide counts only hyperscaler AI revenue, leaving neocloud demand outside it.
Source →Five hyperscalers spent $230.4 billion in one quarter, up 118%, while revenue grew 12% to 30%
The author argues debt-financed AI capex is unsustainable and that several suppliers remain overvalued or face solvency risk despite recent drawdowns.
Five hyperscalers spent $230.4bn in one quarter, up 118% on the year while revenue grew 12% to 30% during that
Frames the gap between capex growth and revenue growth as a risk for AI suppliers.
Source →An NVDA holder is organizing shareholders to explore a Section 220 records demand over Huang's departure
A shareholder holding about $30k of NVDA is organizing fellow holders to demand board answers about Huang's abrupt resignation and to explore a Delaware Section 220 records demand.
NVDA shareholders: can we organise to challenge the board over Jensen's departure? Positions: \~$30k NVDA, held since before Jensen's resignation.
Shows retail holders seeking to challenge the board over the departure.
Source →What would make Anthropic investable at a reported $1.4 trillion valuation?
The author weighs Anthropic's reported ~$1.4T IPO valuation and reported 6x oversubscription against its revenue and huge compute commitments, asking what would make it investable.
Anthropic is reportedly 6× oversubscribed at up to a $1.4T valuation. What would make ANT investable?
Compute commitments sit at the center of the valuation debate.
Source →A poster says Siri failed during the Microsoft outage and favors Apple puts and Microsoft calls
The author claims Siri's failure during the Microsoft outage shows Apple relies on Microsoft cloud hosting, so they favor puts on Apple and calls on Microsoft.
Apple uses Microsoft Cloud for Siri hosting Siri stopped working on my phone when the Microsoft outage began, and still
The author argues the outage exposed Apple's reliance on Microsoft cloud hosting.
Source →Most argued
by comments per upvoteHemisphere Energy is a debt-free heavy-oil producer recovering from a fire, with Q1 2027 restoration the key catalyst
A research write-up presents Hemisphere Energy as a profitable, debt-free heavy-oil producer recovering from a fire that shut in most production.
Hemisphere Energy Corporation (TSXV: HME; OTCQX: HMENF) * Canadian heavy-oil producer operating in Alberta and Saskatchewan. * Q2 2026 revenue:
Restoring production is the key catalyst in the write-up.
Watch Production restoration in Q1 2027.
Source →Kyverna completed its BLA submission for miv-cel in stiff person syndrome
The author is bullish on Kyverna, citing the completed BLA submission for miv-cel in stiff person syndrome, a Phase 3 gMG program, Gilead's ~6.8% stake and ex-KITE/Gilead leadership, and expects a takeover offer within months.
KYTX Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome
The author expects a takeover offer within months.
Source →Elite Pharmaceuticals posted $49.1 million of Q2 FY2027 revenue ahead of a targeted Nasdaq uplisting
A breakdown of the Q2 FY2027 10-Q shows strong sequential revenue and operating income growth, a shrinking warrant overhang and expanding board independence ahead of a February 2027 Nasdaq uplisting target, but also margin erosion and internal-control weaknesses.
Elite phamaceuticals posts $49.1 Millions in revenue for Q2 2027. I analyzed the Sec filing and found this:
Growth comes with margin erosion and internal-control weaknesses.
Watch The February 2027 Nasdaq uplisting target.
Source →A poster projects AMD at $1,200 a share and a $2 trillion market cap by 2028
The author projects a $2T market cap and $1,200 share price by 2028 on $132B of revenue and $40B of net income, noting AMD is over 20% of their portfolio.
AMD $1200 by 2028 I think AMD valuation is justified and it can touch $2T market by 2028.
The author argues AMD's valuation is justified.
Source →A poster watches RSP versus SPY to gauge market breadth
The author watches RSP versus SPY to gauge market breadth and would turn more bullish if equal-weight breadth kept improving for several weeks.
this is why i've beening watching RSP vs.
Equal-weight breadth is the author's signal for turning more bullish.
Watch Equal-weight breadth improving for several weeks.
Source →